<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7C3729AA-933E-4E5E-A502-0DFA7E6E98AD"><gtr:id>7C3729AA-933E-4E5E-A502-0DFA7E6E98AD</gtr:id><gtr:name>Alexion Pharmaceuticals</gtr:name><gtr:address><gtr:line1>352 Knotter Drive</gtr:line1><gtr:postCode>CT 06410</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42144D5C-136B-4ABC-9BA5-E542E2E4D449"><gtr:id>42144D5C-136B-4ABC-9BA5-E542E2E4D449</gtr:id><gtr:name>Octapharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7C3729AA-933E-4E5E-A502-0DFA7E6E98AD"><gtr:id>7C3729AA-933E-4E5E-A502-0DFA7E6E98AD</gtr:id><gtr:name>Alexion Pharmaceuticals</gtr:name><gtr:address><gtr:line1>352 Knotter Drive</gtr:line1><gtr:postCode>CT 06410</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42144D5C-136B-4ABC-9BA5-E542E2E4D449"><gtr:id>42144D5C-136B-4ABC-9BA5-E542E2E4D449</gtr:id><gtr:name>Octapharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8BB7FCDC-1848-4FDC-B679-EC4A2E7D26CB"><gtr:id>8BB7FCDC-1848-4FDC-B679-EC4A2E7D26CB</gtr:id><gtr:firstName>Marie</gtr:firstName><gtr:surname>Scully</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/64459DA2-0473-4C36-AB10-4ACB5B2B4D22"><gtr:id>64459DA2-0473-4C36-AB10-4ACB5B2B4D22</gtr:id><gtr:firstName>Samuel</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Machin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E4E1E0D8-D7E9-436E-B787-68AF8C9D332A"><gtr:id>E4E1E0D8-D7E9-436E-B787-68AF8C9D332A</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Mackie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800671"><gtr:id>735CC335-7251-4C92-96B4-77EFADD66C53</gtr:id><gtr:title>Characterisation of the United Kingdom thrombotic thrombocytopenic purpura (TTP) patient cohort</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800671</gtr:grantReference><gtr:abstractText>Thrombotic thrombocytopenic purpura (TTP) is an acute, sudden onset, life threatening illness, affecting females: males 3:1, typically 30-40 years, but can present at any age between birth and 80 years. The true incidence is unknown, but values of 4-6/million of the population are quoted. Von Willebrand Factor (vWF) with platelets acts to prevent bleeding. VWF is broken down by ADAMTS 13. ADAMTS 13 is missing in TTP. This results in widespread, small vessel thrombosis, affecting all organs, but a variable clinical phenotype. The main treatment is plasma exchange, the removal on a special cell separator machine, of blood plasma and replacement with large volumes of donor plasma, which is a replenishing source of ADAMTS 13. 

The South East (SE) England TTP group have identified TTP subgroups. Cases of congenital TTP, in adults and children require individually based treatment programmes depending on their clinical phenotype. The majority of cases are acquired idiopathic TTP, the majority ( 90%) have antibody, mainly IgG, against ADAMTS 13 and prevent its action. Patients with recurrent or unresponsive TTP episodes were treated with Rituximab, a monoclonal antibody against B-lymphocytes, important in antibody formation. With standard therapy (plasma exchange and steroids) patients have had excellent responses clinically, increases in ADAMTS 13 enzyme levels, decrease in IgG antibody levels and significantly reduced relapses. Approximately 15% of cases have defined precipitating causes, such as HIV, pregnancy or pancreatitis. Some pregnancy cases present as adult congenital TTP and HIV patients require antiretroviral therapy with plasma. 
The aim of the grant is to organise a UK wide TTP registry, to determine the incidence, important epidemiological data regarding patient characteristics and mortality/morbidity in different areas. Baseline ADAMTS 13 assay, repeated in remission, to define if specific antibody levels are associated with related clinical characteristics. Further work on other antibody subtypes/groups within a larger cohort may highlight characteristics in patients not evident from clinical presentation, such as risk of relapse. DNA analysis, in all cases, to determine if mutations or polymorphisms in the ADAMTS 13 gene may be responsible for precipitating subtypes of TTP, or alter responsiveness to therapy. Ultimately, randomised clinical trials, to improve time to remission, by turning off the thrombotic process and improve mortality, using monoclonal antibody therapy. Genetically engineered ADAMTS 13 will be available for congenital TTP.</gtr:abstractText><gtr:technicalSummary>Thrombotic thrombocytopenic purpura (TTP) is an acute life threatening disorder. It typically affects females between 30-40 years, but can present from birth to 80 years. TTP results from a deficiency of the enzyme ADAMTS 13, required for the cleavage (on secretion) of von Willebrand Factor (VWF) converting it from ultra large (ulVWF) molecular forms with excessive platelet reactivity, to normal forms. Lack of ADAMTS13 results in platelet clumping and multi-organ microvascular thrombosis, with resultant clinical sequelae. Identification and treatment is the key to survival; without therapy mortality is 90%; with plasma exchange mortality is 15-20%. Plasma is a source of the missing/dysfunctional enzyme, ADAMTS 13, and plasma exchange using cell separators allows large volumes to be given as well as assisting in removal of ulVWF and ADAMTS13 antibodies. The majority of cases are acquired idiopathic (antibody mediated), but congenital TTP (identified in childhood or adults) and TTP secondary to other conditions make up 20% of all cases. We have presented a local, non-funded, observational, South East England TTP registry, but want to extend this throughout the UK. The aim is to gather important epidemiological information about patient characteristics, mortality/morbidity and treatment availability in the UK. After a review of this data, we the aim to extend multicentre trials to all centres treating TTP. The availability of recombinant ADAMTS13 (rADAMTS13) will be assessed for congenital TTP cases, who would be more easily identified from a UK registry. The adaptation of therapy to individual phenotypes will not only serve to assess the efficacy of rADAMTS 13, but prevent long term sequelae of no treatment. Statistically powered, randomised, controlled trials can only be undertaken when an appropriate cohort of patients are available. It is imperative to attain remission as quickly as possible in acute episodes to prevent long term morbidity or mortality. As idiopathic autoimmune TTP accounts for the majority of the cases, this will be the other primary focus using monoclonal antibody therapy (directed against autoantibody production). Assessment of the baseline and remission ADAMTS13 levels via central analysis will provide more information on the importance of antibody titres and epitope specificity in relation to precipitation of disease. Involving all UK sites and cases will provide a large DNA bank for analysis of ADAMTS13 gene mutations/polymorphisms and allow their importance in the risk of TTP subtypes to be assessed. Ultimately, this will improve the scope of treatment for patients with this devastating disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>485455</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Rheumatology and Bloomsbury Rheumatology Unit</gtr:department><gtr:description>Role of BAFF in the immune response</gtr:description><gtr:id>3572F25B-4CEB-4174-8CB3-6193B173AC88</gtr:id><gtr:impact>european and international poster. Peer reviewed paper</gtr:impact><gtr:outcomeId>NcxQtbhQCkt-1</gtr:outcomeId><gtr:partnerContribution>samples and data from TTP cases</gtr:partnerContribution><gtr:piContribution>samples from acute and follow up TTP cases re the role of BAFF and markers looking at predicting relapse compared to rheumatoid cases</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GWAS</gtr:description><gtr:id>663F5EF1-7A41-4BBE-B6E1-FD5830DA8AC9</gtr:id><gtr:impact>this is a multidisciplinary approach and the outcomes are yet to be identified, but could present very novel proteins associated as a genetic link to aquired disease</gtr:impact><gtr:outcomeId>iyLhNcHMNnS-1</gtr:outcomeId><gtr:partnerContribution>expertise in GWAS and bioanalysis</gtr:partnerContribution><gtr:piContribution>presentation of initial internal data and supply of further samples froom UK TTP registry</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baxter</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Baxter Healthcare</gtr:department><gtr:description>Baxter healthcare</gtr:description><gtr:id>03B2FB54-2EE1-412E-BE6A-BBB1DA006ED8</gtr:id><gtr:impact>as above</gtr:impact><gtr:outcomeId>izisQogBkKL-1</gtr:outcomeId><gtr:partnerContribution>none yet-but important to position the UK for the trials</gtr:partnerContribution><gtr:piContribution>make samples available to progress assay development preceeding phase 1 trials</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK TTP forum</gtr:description><gtr:id>AA5A16B7-AB05-45A0-80CF-72070A2CACD7</gtr:id><gtr:impact>Discussed with NHSBT to create SLAs with specialist centres and 24/7 cover</gtr:impact><gtr:outcomeId>ZVUCK7fJaQ9-1</gtr:outcomeId><gtr:partnerContribution>delivery of 24/7 apheresis service throughout the UK</gtr:partnerContribution><gtr:piContribution>Collaboration with the UK physicans to develop policy and research</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Haematology</gtr:department><gtr:description>collaboration with Imperial hospital scientists</gtr:description><gtr:id>E7F02CBE-CC82-4449-93AC-747168CED44A</gtr:id><gtr:impact>Good working relationships between the 2 groups, with the project impossible without both involved. provides a very experienced scientific group for Dr Thomas' PhD and clinical samples and expertise from UCL</gtr:impact><gtr:outcomeId>SYN8xLMxshW-1</gtr:outcomeId><gtr:partnerContribution>Dr Thomas has excellent access and mentorship with the basic science group</gtr:partnerContribution><gtr:piContribution>Dr Mari Thomas' grant, funded by the BHF, is a dual project between UCL and Imperial, clinical and basic science haemostasis research groups</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alexion Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Alexion UK</gtr:description><gtr:id>89C586BF-F906-4E11-9F5F-9E148A251917</gtr:id><gtr:impact>Audit of cases, for subsequent presentation of frequency</gtr:impact><gtr:outcomeId>PsVPmCj7rtY-1</gtr:outcomeId><gtr:partnerContribution>Use of registry data</gtr:partnerContribution><gtr:piContribution>Use of UK TTP registry to identify the non TTP/Renal causes ?aHUS</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Genomics</gtr:department><gtr:description>GWAS</gtr:description><gtr:id>D33A1D1A-6EEB-4ED1-8315-C40DCF6EB5F1</gtr:id><gtr:impact>this is a multidisciplinary approach and the outcomes are yet to be identified, but could present very novel proteins associated as a genetic link to aquired disease</gtr:impact><gtr:outcomeId>iyLhNcHMNnS-2</gtr:outcomeId><gtr:partnerContribution>expertise in GWAS and bioanalysis</gtr:partnerContribution><gtr:piContribution>presentation of initial internal data and supply of further samples froom UK TTP registry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>ADAMTS 13 assays</gtr:description><gtr:id>B302F8A1-D456-4928-81FD-06B0A833EE72</gtr:id><gtr:impact>not completed</gtr:impact><gtr:outcomeId>eb63QnHCcdL-1</gtr:outcomeId><gtr:partnerContribution>RUN 50/50 WITH SHEFFIELD</gtr:partnerContribution><gtr:piContribution>to undertake UK wide analysis of ADAMTS 13</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>aHUS action</gtr:description><gtr:id>D3E84F82-0A2D-4C00-AA20-E3677336087F</gtr:id><gtr:impact>NHS england have agreed to fund new patients/those failing PEX while going through NICE</gtr:impact><gtr:outcomeId>tXzqith3i6G-1</gtr:outcomeId><gtr:partnerContribution>NHS england have agreed to fund new patients/those failing PEX while going through NICE</gtr:partnerContribution><gtr:piContribution>collaboration to ensure diagnosis and treatment availability for aHUS patients</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Octapharma</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Octapharma</gtr:description><gtr:id>BA3FEB01-F393-4C4D-962D-1C8161AEBF7C</gtr:id><gtr:impact>outputs are:
data on Octaplas use since 1.1.2006
2. review safety for 6 months use of Octaplas LG when introduced</gtr:impact><gtr:outcomeId>PT6Bjt1EarA-1</gtr:outcomeId><gtr:partnerContribution>funding support for trial coordinator</gtr:partnerContribution><gtr:piContribution>relationship over many years, to review new plasma and data on previous plasma use</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Genomics</gtr:department><gtr:description>GWAS</gtr:description><gtr:id>CC8E60F2-4963-45B2-951B-1B6BF273DAAB</gtr:id><gtr:impact>awaiting final results</gtr:impact><gtr:outcomeId>FAf7po3gXdH-2</gtr:outcomeId><gtr:partnerContribution>expertise in genomics and bioanalysis</gtr:partnerContribution><gtr:piContribution>expertise in all 3 areas to progress GWAS study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>congenital TTP assays</gtr:description><gtr:id>C3877BF2-B5D7-4F8D-97D1-D7EB3132EAAD</gtr:id><gtr:impact>Paper in Blood journal</gtr:impact><gtr:outcomeId>nU411yAXQFt-1</gtr:outcomeId><gtr:partnerContribution>international collaboration led by a post doc in Milan</gtr:partnerContribution><gtr:piContribution>access to UK TTP congenital samples for the project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GWAS</gtr:description><gtr:id>29050D39-918E-456D-948D-8140FF06E43A</gtr:id><gtr:impact>awaiting final results</gtr:impact><gtr:outcomeId>FAf7po3gXdH-1</gtr:outcomeId><gtr:partnerContribution>expertise in genomics and bioanalysis</gtr:partnerContribution><gtr:piContribution>expertise in all 3 areas to progress GWAS study</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>meeting in parliment</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>89648255-D8BE-44B2-99BD-C3191653F980</gtr:id><gtr:impact>pressure on government to support specialist services

awaiting parliments response</gtr:impact><gtr:outcomeId>o3z8XM2WT8M</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TTP Patient day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8912D0EC-1B26-4711-8469-B5F7B27787E1</gtr:id><gtr:impact>UK TTP patient day, with 80 patients and family from around the UK. All the TTP team presented their recent work including all the staff funded from the MRC grant

Feedback evaluation forms-appears very successfula dn informative. Many wanted a repeat day in the near future</gtr:impact><gtr:outcomeId>HDmfghZtgtV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA-SWG</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>106CA6B9-7463-496D-9E30-7FAD56D11226</gtr:id><gtr:impact>developing an international consensus document

international collaboration of lead haemaatologists, renal physicans and academics</gtr:impact><gtr:outcomeId>LqoKDM1UUEL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK TTP forum</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53E4BEFC-E3A8-4C16-B3C6-69DB79B0266E</gtr:id><gtr:impact>25 attendees. Primary aim: to ensure 24/7 apheresis for all sites in the UK. Attendance increased year upon year. specialist service specification and discussion with national commissioners. Update on clinical trials and centre participation

Discussions with NHSBT following the meeting. Discussion with commissioners</gtr:impact><gtr:outcomeId>HE3uqdav8iC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>specialist appraisal group of NICE</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C5A68B16-6FEF-448E-B0F9-D00AB2772169</gtr:id><gtr:impact>Initiation of a specialist appraisal group for rare diseases, specifically ecluzimab in aHUS

Experts in the firld of TMAs in the UK to advise re benefit of ecluzimab in aHUS following AGNESS report</gtr:impact><gtr:outcomeId>ATAym4MMYtS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Unrestricted educational grant</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Alexion Pharmaceuticals</gtr:fundingOrg><gtr:id>816E8EB8-EBFF-4D72-AEAC-40521346F312</gtr:id><gtr:outcomeId>Txa43V4DuDT</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ADAMTS 13 assays</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Alexion Pharmaceuticals</gtr:fundingOrg><gtr:id>AF70DFD3-99D3-41B4-970A-D37F1528F045</gtr:id><gtr:outcomeId>SFbYWHbuY22</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Unrestricted educational grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Octapharma</gtr:fundingOrg><gtr:id>21461139-D851-4E95-A9A1-22E38430D695</gtr:id><gtr:outcomeId>HCeWTL7wgMR</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>204778</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>clinical research training fellowship</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>E8606016-4176-478E-8E13-DAAE3C619160</gtr:id><gtr:outcomeId>VxsGbZ5hYe30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>non surgical</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Baxter</gtr:fundingOrg><gtr:id>CD021A21-00A1-45EF-B8F7-7836C6A3F74B</gtr:id><gtr:outcomeId>546134512282f3.37761826</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BCSH guidelines on TTP na dthrombotic microangiopathies</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>517EDA09-3538-4A62-BA67-CA388E011EBC</gtr:id><gtr:impact>Improved understanding of TTP and TMAs has increased the diagnosis of these disorders</gtr:impact><gtr:outcomeId>gWgFYv9b7dG</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Octaplas data</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>4FFAA82B-23F6-4E19-9C69-66CE0D509E97</gtr:id><gtr:impact>Use of a safer plasma product to Canada for TTP patients</gtr:impact><gtr:outcomeId>UieVHTwt2hg</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>local and national talks to increase awaremess of TTP</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>92EAFFE6-403D-411B-A59D-6E317ACADAD7</gtr:id><gtr:impact>Improved awareness in TTP, such that it is now recognised as an acute emergency that needs to be excluded, not only in haematology, but also in other specialities eg medicine, renal and intensive care. The output is the increased number of acute cases, real or suspected which the registry is capturing</gtr:impact><gtr:outcomeId>HFcSXU8CYXK</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Presenting Octaplas data</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>AEBC8A47-5F43-4BC1-AFA6-6F44732C60DD</gtr:id><gtr:impact>use of double viral inactivated plasma, which is safer, to the USA for TTP</gtr:impact><gtr:outcomeId>XkTgVWbNAWi</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>british society of haematology-obstetric group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D4F17A3E-A4E8-4B6D-AEE5-8D432C60C75F</gtr:id><gtr:impact>presentation x 2 (2012 and 2010 ) of data on congenital TTP-late onset-in pregnancy, management and frequency</gtr:impact><gtr:outcomeId>ct5V6maHEjR</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>aHUS action</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>119FCA6B-8174-4DE3-9215-096479DB6759</gtr:id><gtr:impact>raised awarenedss of aHUS and leading to presentation of complement inhibitors as therapy</gtr:impact><gtr:outcomeId>srsF3nubYnq</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>nanobody in acute TTP-International trial

phase 2 completed-phase 3 in development</gtr:description><gtr:id>D79B425D-6BEF-4B68-A64F-40542117E806</gtr:id><gtr:impact>novel therapy in a rare disease</gtr:impact><gtr:outcomeId>5461362d707704.89804048</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ablynx trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>RECOMBINANT THERAPY IN CONGENITAL TTP</gtr:description><gtr:id>D03A2483-54FC-4A94-B564-2365FB3A6FF8</gtr:id><gtr:impact>FIRST IN HUMAN THERAPY</gtr:impact><gtr:outcomeId>546136b2af1bb5.53815704</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>recombinant ADAMTS 13</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>web based NHS compliant database incorporating the CRF nationally</gtr:description><gtr:id>50E25A81-405D-47DB-B0AC-18C96AAEE0D6</gtr:id><gtr:impact>this is the largest international database for this disorder</gtr:impact><gtr:outcomeId>54627f5bb23534.10510666</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK TTP registry</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>FRETS technlogy has resulted in assays within 2 hours rather than 3 days. Fully validated and comparable to previous assays</gtr:description><gtr:id>32270723-5BDE-429B-85C2-35DDCF723731</gtr:id><gtr:impact>quicker assay times</gtr:impact><gtr:outcomeId>CkbiUq9qdpm</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FRETS assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Identification of a number of late onset congenital cases related to pregnancy</gtr:description><gtr:id>3A7038B4-E4A6-410A-909B-CBD3861055A9</gtr:id><gtr:impact>treatment protocols in subsequent pregnancies have been identified/developed on the basis of all the cases submitted via the registry-largest cohort internationally</gtr:impact><gtr:outcomeId>AYNYEu11tHK</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>UK TTP Registry and DNA bank</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In house development-only commercial kits available</gtr:description><gtr:id>1A580F60-85F9-44C2-9169-32BEE1B3789E</gtr:id><gtr:impact>useful for aHUS cases-previously only sent to Newcastle</gtr:impact><gtr:outcomeId>ExTLKYonTFM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>factor H assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>using samples from the registry and other research groups, reviewing the role of complement and cytokines in TTP , other TMAs and allied medical disorders</gtr:description><gtr:id>8E83EA41-5CE4-4036-8E76-F556D3320400</gtr:id><gtr:impact>understanding of role of complement in specific disease states</gtr:impact><gtr:outcomeId>g474jBypWod</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>complement assays</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data from registry cases (and previous non registry cases)</gtr:description><gtr:id>C5B6A736-0B57-4684-AB52-31C589829163</gtr:id><gtr:impact>presentation in a peer reviewed journal and oral presentation at EHA</gtr:impact><gtr:outcomeId>nVkkFRS1USL</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>use of rituximab in TTP</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>data and samples</gtr:description><gtr:id>0721E661-4293-4432-B234-CDF98220C9C5</gtr:id><gtr:impact>review of non TTP cases had not initally been a significant part of the registry, although data was being captured. With new medications for aHUS, this has become more relevant and may highlight cases not previously diagnosed</gtr:impact><gtr:outcomeId>BtPVLJNtqgF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>non TTP cases</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>43B3F655-A432-4607-842B-75F606BB589F</gtr:id><gtr:title>Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20ffdad97b7b83bd4a8ce766f252f2ea"><gtr:id>20ffdad97b7b83bd4a8ce766f252f2ea</gtr:id><gtr:otherNames>Peyvandi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>5aa30c9bb0c046.57095265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>899FEC3D-D608-4B7D-9336-E3B961D64E01</gtr:id><gtr:title>Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fcd7e09e4f5be43f208a33ff1f1c40e"><gtr:id>5fcd7e09e4f5be43f208a33ff1f1c40e</gtr:id><gtr:otherNames>Becerra E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5461337adaaf05.05064833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39E9B05C-F89F-4CFF-A1BC-2CF9CD3ADF0D</gtr:id><gtr:title>Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy.</gtr:title><gtr:parentPublicationTitle>Hematology. American Society of Hematology. Education Program</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1520-4383</gtr:issn><gtr:outcomeId>5aa30b4797fb60.71767852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43465CC1-26E7-438F-B91D-EB81EFC28838</gtr:id><gtr:title>First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12bcdbf260f796e875bef74f60ec5a7f"><gtr:id>12bcdbf260f796e875bef74f60ec5a7f</gtr:id><gtr:otherNames>Bramham K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13781_21_21527518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87F61F35-4938-43C6-B792-4FAD2CAF1F5D</gtr:id><gtr:title>A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1117ec354b47a74363508b47ae48d2b5"><gtr:id>1117ec354b47a74363508b47ae48d2b5</gtr:id><gtr:otherNames>Camilleri RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_13781_21_22783805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9F00A88-5964-4366-91E5-66843C62D53D</gtr:id><gtr:title>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20ffdad97b7b83bd4a8ce766f252f2ea"><gtr:id>20ffdad97b7b83bd4a8ce766f252f2ea</gtr:id><gtr:otherNames>Peyvandi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5aa307c17369e6.43084815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24D3822B-1B5E-4486-85D2-87199217EA3D</gtr:id><gtr:title>Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy.</gtr:title><gtr:parentPublicationTitle>Seminars in thrombosis and hemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0094-6176</gtr:issn><gtr:outcomeId>5aa30b48250210.81278014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CFE6E0C-5449-469D-A147-AB225320EDAE</gtr:id><gtr:title>Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18da1b10d29adfd82fc07718b0dc32b"><gtr:id>f18da1b10d29adfd82fc07718b0dc32b</gtr:id><gtr:otherNames>Thomas MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>56ce266ced4a74.27665693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B4290F-1AD9-453B-9231-3852E5362D6E</gtr:id><gtr:title>Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5461337a1c6dd5.33410204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>473A3BCB-0585-4D5F-939E-0B1D84D6F3C1</gtr:id><gtr:title>The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cf190801a009a97de3a4018536a7f03"><gtr:id>6cf190801a009a97de3a4018536a7f03</gtr:id><gtr:otherNames>Phillips EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>56ce266cb0a8e5.50934838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D8CCA25-66D4-4485-8F3F-A492A0A5B072</gtr:id><gtr:title>How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5461337a4343d1.90854995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3622C4DF-FC6A-4519-A31D-0A58FEDFF3D2</gtr:id><gtr:title>Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb2fcb28e92e8da3ecabe91d120b1ab"><gtr:id>9fb2fcb28e92e8da3ecabe91d120b1ab</gtr:id><gtr:otherNames>Crowley MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5aa30a8da8c8a5.38783542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0317A150-AEB6-4825-A7EF-2432FC64D31E</gtr:id><gtr:title>Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15506d85f8bee4016b396e7203341775"><gtr:id>15506d85f8bee4016b396e7203341775</gtr:id><gtr:otherNames>Taylor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa30e42ebe249.10723374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D44FB5E-FE5D-4628-8819-5E69D68483F5</gtr:id><gtr:title>Management of thrombotic thrombocytopenic purpura: current perspectives.</gtr:title><gtr:parentPublicationTitle>Journal of blood medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9f14e6ed6f7437a252325b60e0b9b2d"><gtr:id>f9f14e6ed6f7437a252325b60e0b9b2d</gtr:id><gtr:otherNames>Blombery P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1179-2736</gtr:issn><gtr:outcomeId>5461337a67dac3.51735761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98A1712F-5ECC-4D90-A50D-D72C1D721807</gtr:id><gtr:title>Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>5aa30b47cf9c49.38583774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E95CA5A-138A-4B01-80CB-AEFDAC2A7E25</gtr:id><gtr:title>Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25911a14a8486144842824916bbd20d3"><gtr:id>25911a14a8486144842824916bbd20d3</gtr:id><gtr:otherNames>McCabe DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>56ce266e12bc34.36833399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>466B6212-C5A1-4DBD-9549-FCCEB0F992BE</gtr:id><gtr:title>Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays.</gtr:title><gtr:parentPublicationTitle>International journal of laboratory hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faef21cc81573fe5f626b62cdafa3651"><gtr:id>faef21cc81573fe5f626b62cdafa3651</gtr:id><gtr:otherNames>Langley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1751-5521</gtr:issn><gtr:outcomeId>5aa30b7eb59336.20192057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4984633-A791-4B1C-A35F-82BA7A634D95</gtr:id><gtr:title>Thrombotic thrombocytopenic purpura associated with statin therapy.</gtr:title><gtr:parentPublicationTitle>Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18da1b10d29adfd82fc07718b0dc32b"><gtr:id>f18da1b10d29adfd82fc07718b0dc32b</gtr:id><gtr:otherNames>Thomas MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0957-5235</gtr:issn><gtr:outcomeId>pm_13781_21_22198366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2F55F9-0285-42B9-AAA4-403A8D362E9A</gtr:id><gtr:title>The role of complement activation in COPD exacerbation recovery.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn><gtr:outcomeId>5aa30ac6e1bd20.00944382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FECA1D00-B0BB-434D-9596-B016A07D9DA4</gtr:id><gtr:title>A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a396d80c3aa905acf0079c053d0ee097"><gtr:id>a396d80c3aa905acf0079c053d0ee097</gtr:id><gtr:otherNames>Thachil J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa30eff3ed994.21654695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68F955FB-7C50-42FE-ACC0-7369A239F699</gtr:id><gtr:title>Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Oncoscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2331-4737</gtr:issn><gtr:outcomeId>5aa3095255fff4.85248309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46E9C423-7320-4F4E-892C-FD5063370203</gtr:id><gtr:title>Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3068dc80b3c59e24e9fd90a3cd9d5a"><gtr:id>7d3068dc80b3c59e24e9fd90a3cd9d5a</gtr:id><gtr:otherNames>Mackie I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>pm_13781_21_23306535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98172891-1ECA-4704-B0C9-FC2C6EB745CB</gtr:id><gtr:title>How we manage patients with heparin induced thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa30b48495662.98012247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0A73D41-86D7-418E-84AD-98E18C637F20</gtr:id><gtr:title>Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad2189b4a57dbaeb75d3d2e485b13cdf"><gtr:id>ad2189b4a57dbaeb75d3d2e485b13cdf</gtr:id><gtr:otherNames>Azoulay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5aa30d669a6cc9.46507034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AF27A99-C2C4-44B0-895B-FB37D60DF428</gtr:id><gtr:title>Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3677fff7e8e7835c6a6b4e5b2c903158"><gtr:id>3677fff7e8e7835c6a6b4e5b2c903158</gtr:id><gtr:otherNames>Brown JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_13781_21_22420623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>773903D4-46DC-4FAB-A7DD-D4711A31C2E0</gtr:id><gtr:title>Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5461337a8f2626.54608321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>376F0407-2BFD-436A-855C-38880F573CE6</gtr:id><gtr:title>Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience.</gtr:title><gtr:parentPublicationTitle>Vox sanguinis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b23ac65bb758cc5d336d0d2be993b49"><gtr:id>9b23ac65bb758cc5d336d0d2be993b49</gtr:id><gtr:otherNames>McGuckin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-9007</gtr:issn><gtr:outcomeId>pm_13781_21_24117855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>336009E0-8297-485F-9F22-51090572624F</gtr:id><gtr:title>A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>G7GFceJaSeY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDCFB1AF-AE67-450E-86CA-023B9367E806</gtr:id><gtr:title>Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13781_21_22624596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62163D3A-9BE1-41A2-BF88-4D5D0685B2DE</gtr:id><gtr:title>Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f262bfd701a417cb4ccac943da2f8d0"><gtr:id>6f262bfd701a417cb4ccac943da2f8d0</gtr:id><gtr:otherNames>McDonald V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>P24SLZfY8Uc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AF8F13F-A635-4EFE-9237-34A0B8A2391D</gtr:id><gtr:title>How I treat disseminated intravascular coagulation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bde7d04766ba6a263f142fb0608ad51"><gtr:id>7bde7d04766ba6a263f142fb0608ad51</gtr:id><gtr:otherNames>Levi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5aa30a20e4ca43.98838445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>717A7F76-833C-4198-95BC-199C93593658</gtr:id><gtr:title>Cancer and Thrombotic Microangiopathy.</gtr:title><gtr:parentPublicationTitle>Journal of oncology practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-7477</gtr:issn><gtr:outcomeId>5aa30b4801ecb9.07059392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CACB512-6B51-4652-B422-D8DA8C5E43F1</gtr:id><gtr:title>Recurrent brain ischaemia and deep vein thrombosis: the clot thickens.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e2d0947beef3a4da746fc9d89cbb670"><gtr:id>0e2d0947beef3a4da746fc9d89cbb670</gtr:id><gtr:otherNames>Turner D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>5aa30c1ccb5289.74663930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFE42B05-9975-4113-A6CD-FA24F4F429C7</gtr:id><gtr:title>A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a725c099a8e4858ca5a895972efe144e"><gtr:id>a725c099a8e4858ca5a895972efe144e</gtr:id><gtr:otherNames>Vendramin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>5aa30f55200da5.87711866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F696DE95-D375-4CE1-B7F1-84BA7889CB31</gtr:id><gtr:title>The role of ADAMTS-13 in the coagulopathy of sepsis.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bde7d04766ba6a263f142fb0608ad51"><gtr:id>7bde7d04766ba6a263f142fb0608ad51</gtr:id><gtr:otherNames>Levi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>5aa30a20bae537.23054452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CFD7B83-016F-4CB8-9ABD-4FC804B2DA82</gtr:id><gtr:title>Mycophenolate mofetil therapy for severe immune thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15506d85f8bee4016b396e7203341775"><gtr:id>15506d85f8bee4016b396e7203341775</gtr:id><gtr:otherNames>Taylor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56ce266d5f7eb9.16138440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB6FAEF8-CB5A-4CB9-A496-0C38DEAB4A0F</gtr:id><gtr:title>Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.</gtr:title><gtr:parentPublicationTitle>Blood advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2473-9529</gtr:issn><gtr:outcomeId>5aa30ac6acae67.07032408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38ABBCA7-EA59-4A20-888B-00272B846F6E</gtr:id><gtr:title>The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c640954e72ae94095e182bbfad5fdfc"><gtr:id>1c640954e72ae94095e182bbfad5fdfc</gtr:id><gtr:otherNames>Hassan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56ce266d26d491.15860139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFE01DB1-2AE5-4BA6-BBB3-9FAA7718910D</gtr:id><gtr:title>Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10b272a736d60ae58474ac039b9efd0b"><gtr:id>10b272a736d60ae58474ac039b9efd0b</gtr:id><gtr:otherNames>Alwan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5aa30c588a9b06.60371735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C72A1007-B6D1-4F55-8158-0697D858A90A</gtr:id><gtr:title>A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres--providing better outcomes.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e83c2593fde02103132cc2e3d0ccb6b"><gtr:id>4e83c2593fde02103132cc2e3d0ccb6b</gtr:id><gtr:otherNames>Dutt T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56ce266d8e4fb5.33422625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C8153CE-9553-45B2-82A2-2E0E58677E76</gtr:id><gtr:title>Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abb983d455946dbdc88fb0f603c536be"><gtr:id>abb983d455946dbdc88fb0f603c536be</gtr:id><gtr:otherNames>Hart D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>BqtUKo9NeEj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>177E819C-CDC0-471B-9EFE-2723AF792B1D</gtr:id><gtr:title>B cell activating factor is elevated in acute idiopathic thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18da1b10d29adfd82fc07718b0dc32b"><gtr:id>f18da1b10d29adfd82fc07718b0dc32b</gtr:id><gtr:otherNames>Thomas MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>WBQ5K45wxDg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>575A2F90-7AB6-492C-AF3E-3048280598C7</gtr:id><gtr:title>Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/590c8a9618b273cc7c1e0848dd49db27"><gtr:id>590c8a9618b273cc7c1e0848dd49db27</gtr:id><gtr:otherNames>Lotta LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13781_21_22529288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80005C2-C311-49AF-A5ED-122E7C97BED8</gtr:id><gtr:title>Rituximab in the treatment of TTP.</gtr:title><gtr:parentPublicationTitle>Hematology (Amsterdam, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1024-5332</gtr:issn><gtr:outcomeId>pm_13781_21_22507771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E4365FC-44FB-491B-8EE6-1C063EF24D2D</gtr:id><gtr:title>Trends in the diagnosis and management of TTP: European perspective.</gtr:title><gtr:parentPublicationTitle>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-0502</gtr:issn><gtr:outcomeId>5461337ab6f229.85392677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>276FF9F7-B7F5-4EC8-8ECF-0D355C16B81D</gtr:id><gtr:title>Rituximab in Thrombotic Thrombocytopenic Purpura: Medical and Financial Benefits.</gtr:title><gtr:parentPublicationTitle>Acta haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-5792</gtr:issn><gtr:outcomeId>56ce266dda1358.44461814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C81F647B-9866-4622-9B4C-FC3689FE5034</gtr:id><gtr:title>Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_13781_21_23279219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E62549FE-4EFD-4EEC-9831-1B6B8296D843</gtr:id><gtr:title>Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5aa309521a4564.34767287</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800671</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>